Innovation against cancer: a scientific congress rooted in collaboration

On 22 September 2016, we launched our first Innovation Scientific Congress, held at the CEME in Charleroi. This first edition was dedicated to cancer, a disease that remains one of the most significant public health challenges worldwide.

The event brought together a diverse network of stakeholders from the pharmaceutical industry, academic research, and regulatory authorities, both national and international. The aim was to foster dialogue and share expertise around the development of innovative oncology medicines.

Throughout the day, speakers and attendees exchanged insights on the latest scientific and regulatory advances, discussed analytical strategies for complex molecules, and explored collaborative approaches to accelerate innovation. The congress highlighted the importance of cross-sector collaboration in addressing the complexity of cancer and in bringing effective therapies to patients.

This initiative reflects our long-standing commitment to the fight against cancer. Back in 2015, the company’s involvement in oncology represented:

• 19 partnerships with biotech companies,
• 32 innovative products in development,
• and 55% of its annual revenue.

This deep engagement in cancer research goes beyond scientific expertise. It also extends to solidarity and public support, notably through Quality Assistance’s ongoing involvement with Télévie, a cause the company has supported for many years. By combining scientific excellence with social commitment, Quality Assistance contributes to advancing cancer research on multiple fronts.

By organizing this congress, we reaffirmed our role as a facilitator of scientific exchange and progress. This first edition laid the foundation for a series of future congresses, each focused on a major health issue, and confirmed that innovation must always serve people.

Watch the aftermovie

With the support of :

• SRIW
• ING
• BNP Paribas Fortis
• Sambrinvest
• Biopark
• Essenscia